Elucidating the roles of CACNA2D2 and CACNA2D3 in presynaptic regulation of mammalian synaptic function
Project Number1R03TR004161-01
Contact PI/Project LeaderYOUNG, SAMUEL MATTHEW
Awardee OrganizationUNIVERSITY OF IOWA
Description
Abstract Text
Project Summary/Abstract
Synapses are the fundamental unit of information transfer in the central nervous system (CNS)
and are composed a highly complex molecular machinery that tightly regulates synaptic
transmission and neuronal circuit output. A multitude of combinations of synaptic proteins and
their isoforms creates synapses with distinct functional properties to enable the broad diversity of
information encoding by neuronal circuits. Human mutations in synaptic proteins result in synaptic
dysfunction which causes neurological disorders such as schizophrenia, epilepsy, ataxia, autism,
and intellectual disability. Currently, 1.5 billion people worldwide suffer from a CNS disorder,
however there are limited therapeutic options. Therefore, elucidating the molecular mechanisms
that control synaptic function are fundamental to developing novel therapeutics for CNS disorders.
The α2δ proteins (α2δ 1-4) are extracellular proteins initially identified as auxiliary subunits of
voltage-gated Ca2+ (CaV) channel complexes and they are drug targets. However, multiple roles
have been described for the α2δ isoforms in independently regulating synaptic function and CaV
channel complexes. Human mutations specific to each α2δ isoform are correlated to distinct brain
disorders. Despite being highly expressed throughout the CNS and the clear linkage between
human mutations in α2δ2 and α2δ3 and CNS disorders, very little is known about the roles of
α2δ2 and α2δ3 in regulating synaptic function. In mammals, the globular bushy cells (GBCs) in
the auditory brainstem highly express both α2δ2 and α2δ3. The GBC axon gives rise to the calyx
of Held, a glutamatergic presynaptic terminal which is the sole input to drive action-potential (AP)
spiking and utilizes rapid, temporally precise AP signaling to encode auditory information. The
calyx is an exceptional model for gaining mechanistic insights into the presynaptic regulation of
synaptic function and neuronal circuit output Therefore our goal is to establish how presynaptic
α2δ2 and α2δ3 regulate synaptic function and neuronal circuit output. We will use novel
transgenic mouse models and viral vectors to manipulate the α2δ2 and α2δ3 at the calyx during
different developmental stages and analyze how their loss impact synaptic transmission and
neuronal circuit output.. Ultimately, our findings will provide fundamental insights into how
information is encoded by the CNS and will facilitate the development of treatments for a wide
range of neurological disorders due to α2δ2 and α2δ3 mutations. Finally, our novel animal models
will be valuable reagents to the Illuminating the Druggable Genome (IDG) program
Public Health Relevance Statement
Project Narrative
The goal of this project is to is to establish how α2δ2 and α2δ3 regulate synaptic function and
neuronal circuit output. Despite being highly expressed throughout the central nervous system
(CNS) and the clear linkage between human mutations in α2δ2 and α2δ3 and CNS disorders,
very little is known about the roles of α2δ2 and α2δ3 in regulating synaptic function. Therefore,
our findings will provide fundamental insights into how information is encoded by the CNS and
will facilitate the development of treatments for a wide range of neurological disorders due to α2δ2
and α2δ3 mutations.
No Sub Projects information available for 1R03TR004161-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R03TR004161-01
Patents
No Patents information available for 1R03TR004161-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R03TR004161-01
Clinical Studies
No Clinical Studies information available for 1R03TR004161-01
News and More
Related News Releases
No news release information available for 1R03TR004161-01
History
No Historical information available for 1R03TR004161-01
Similar Projects
No Similar Projects information available for 1R03TR004161-01